The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Key Laboratory of Biotherapy and Regenerative Medicine of Gansu Province, Lanzhou, China.
Stem Cell Res Ther. 2022 Jul 26;13(1):356. doi: 10.1186/s13287-022-03041-5.
Cost-effective treatment strategies for liver fibrosis or cirrhosis are limited. Many clinical trials of stem cells for liver disease shown that stem cells might be a potential therapeutic approach. This review will summarize the published clinical trials of stem cells for the treatment of liver fibrosis/cirrhosis and provide the latest overview of various cell sources, cell doses, and delivery methods. We also describe the limitations and strengths of various stem cells in clinical applications. Furthermore, to clarify how stem cells play a therapeutic role in liver fibrosis, we discuss the molecular mechanisms of stem cells for treatment of liver fibrosis, including liver regeneration, immunoregulation, resistance to injury, myofibroblast repression, and extracellular matrix degradation. We provide a perspective for the prospects of future clinical implementation of stem cells.
治疗肝纤维化或肝硬化的经济有效的方法有限。许多干细胞治疗肝病的临床试验表明，干细胞可能是一种有潜力的治疗方法。本综述将总结已发表的干细胞治疗肝纤维化/肝硬化的临床试验，并提供各种细胞来源、细胞剂量和输送方法的最新概述。我们还描述了各种干细胞在临床应用中的局限性和优势。此外，为了阐明干细胞在肝纤维化中的治疗作用，我们讨论了干细胞治疗肝纤维化的分子机制，包括肝再生、免疫调节、抗损伤、肌成纤维细胞抑制和细胞外基质降解。我们为干细胞未来临床应用的前景提供了一个视角。
